Virus Adaptation and Treatment最新文献

Mayaro virus: the jungle flu 玛雅罗病毒:丛林流感

Virus Adaptation and Treatment Pub Date : 2018-04-11 DOI: 10.2147/VAAT.S128711

R. Izurieta, David A DeLacure, A. Izurieta, Ismael Hoare, M. Ortiz

引用次数: 13

Management strategies of enterovirus D68 outbreaks: current perspectives 肠道病毒D68暴发的管理策略:当前观点

Virus Adaptation and Treatment Pub Date : 2018-03-13 DOI: 10.2147/VAAT.S140376

N. Milhano, K. S. Borge, K. Bragstad, S. Dudman

引用次数: 1

Lujo virus: current concepts Lujo病毒:当前概念

Virus Adaptation and Treatment Pub Date : 2017-12-07 DOI: 10.2147/vaat.s113593

N. Sewlall, J. Pawęska

引用次数: 2

Usutu virus: current knowledge and future perspectives 乌苏图病毒:目前的认识和未来的展望

Virus Adaptation and Treatment Pub Date : 2017-10-16 DOI: 10.2147/VAAT.S123619

J. Saiz, A. Blázquez

{"title":"Usutu virus: current knowledge and future perspectives","authors":"J. Saiz, A. Blázquez","doi":"10.2147/VAAT.S123619","DOIUrl":"https://doi.org/10.2147/VAAT.S123619","url":null,"abstract":": The Flavivirus genus (Flaviviridae family) contains important pathogens such as yellow fever virus, Japanese encephalitis virus, St Louis encephalitis virus, West Nile virus, Usutu virus (USUV), Zika virus, and dengue virus, many of which constitute a worrisome threat to global human and animal health. USUV is transmitted by mosquitoes and, as any other flavivirus, is an enveloped plus-strand RNA virus. The virus was first isolated from Culex neavei mosquitoes in South Africa in 1959 near the Usutu River, from where it takes its name. Since then, the virus was confined to Africa until its first detection in Austria in 2001, although it was probably present in Europe since 1996 or even earlier. After that, USUV has spread throughout Europe, causing a considerable mortality among birds and a few neurologic cases in humans. The main USUV natural hosts are birds, but infection has also been reported in other vertebrate species, including humans. The fast spread of the virus through the continent, the relatively high mortality caused in birds, and the recent neuroinvasive human cases related to USUV infection reported in Europe have raised serious concerns about its possible consequences for public health. Here, an updated review of current knowledge about this emerging pathogen is presented.","PeriodicalId":337688,"journal":{"name":"Virus Adaptation and Treatment","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116664844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Bovine leukemia virus: current perspectives 牛白血病病毒:目前的观点

Virus Adaptation and Treatment Pub Date : 2017-08-10 DOI: 10.2147/VAAT.S113947

M. Juliarena, Clarisa Natalia Barrios, C. Lützelschwab, E. Esteban, S. Gutiérrez

引用次数: 24

The Guillain–Barrè peptide signatures: from Zika virus to Campylobacter, and beyond Guillain-Barrè肽特征:从寨卡病毒到弯曲杆菌，以及其他

Virus Adaptation and Treatment Pub Date : 2017-08-01 DOI: 10.2147/VAAT.S124535

G. Lucchese, D. Kanduc

引用次数: 5

Phosphorylation of the viral coat protein regulates RNA virus infection 病毒外壳蛋白磷酸化调控RNA病毒感染

Virus Adaptation and Treatment Pub Date : 2016-11-24 DOI: 10.2147/VAAT.S118440

Haley Hoover, C. Kao

引用次数: 4

Porcine epidemic diarrhea virus: current insights 猪流行性腹泻病毒:目前的见解

Virus Adaptation and Treatment Pub Date : 2016-05-30 DOI: 10.2147/VAAT.S107275

C. Lv, Yan Xiao, Xiangdong Li, K. Tian

引用次数: 25

Recent advances in host–virus interactomics during entry and infection 进入和感染过程中宿主-病毒相互作用学的最新进展

Virus Adaptation and Treatment Pub Date : 2015-12-01 DOI: 10.2147/VAAT.S60265

S. Bhattacharjee

引用次数: 2

Impact and differential clinical utility of cobicistat-boosted darunavir in HIV/AIDS 复方达鲁那韦对HIV/AIDS的影响和临床应用差异

Virus Adaptation and Treatment Pub Date : 2015-08-21 DOI: 10.2147/VAAT.S83680

M. Cossu, N. Astuti, A. Capetti, G. Rizzardini

{"title":"Impact and differential clinical utility of cobicistat-boosted darunavir in HIV/AIDS","authors":"M. Cossu, N. Astuti, A. Capetti, G. Rizzardini","doi":"10.2147/VAAT.S83680","DOIUrl":"https://doi.org/10.2147/VAAT.S83680","url":null,"abstract":": Cobicistat (Cobi) is a pharmacoenhancer, without anti-HIV activity, that optimizes systemic exposures of protease inhibitors (PIs) such as atazanavir (ATV) and darunavir (DRV). In particular, Cobi is a potent inhibitor of cytochrome P450 (CYP) 3A enzymes, the main metabolizing pathway of this class of antiretrovirals. Due to its more selective inhibition of CYP3A, Cobi has a lower potential for off-target drug interactions than the standard boosting agent ritonavir (RTV), and lower likelihood for enzymatic induction. In pharmacokinetic studies of healthy volunteers, DRV boosted with Cobi attains plasma concentrations that are comparable to those achieved with 100 mg RTV as booster. In Phase III clinical trials, conducted in naïve subjects, the coformulation yielded high rates of suppression of viral replication, on average 82%–83% of treated patients reaching undetectable viremia after 48 weeks of therapy. The selection of resistance associated with mutations was a rare event and no phenotypic resistance to DRV emerged in viral failures. Generally, Cobi was well tolerated; however, it has been shown to decrease estimated creatinine clearance (ClCr) due to inhibition of tubular secretion of creatinine. Cobi, therefore, should not be initiated in patients with ClCr less than 70 mL/min, if any coadministered agent (eg, emtricitabine, lamivudine, tenofovir disoproxil fumarate, or adefovir) requires dose adjustment based on ClCr.DRV/Cobi fixed-dose combination is part of an important evolution of antiretroviral therapy toward simpler yet potent formulations. In this setting, it is important to combine potency, simplicity, safety, and high genetic barrier, as in this case.","PeriodicalId":337688,"journal":{"name":"Virus Adaptation and Treatment","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121518342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4